Lifeward Ltd. has entered into a definitive agreement to acquire the technology assets and know‑how of Skelable Ltd., a developer of a powered upper‑body orthotic device that incorporates artificial‑intelligence‑driven therapy recommendations. The deal is valued at $480,000 in Lifeward equity, payable in installments tied to milestone achievements, and includes a nominal cash payment at closing.
The acquisition adds a new product line that complements Lifeward’s existing ReWalk personal exoskeletons and AlterG anti‑gravity systems. By integrating Skelable’s AI‑driven upper‑limb technology, Lifeward aims to offer a comprehensive, whole‑body neuro‑rehabilitation platform that can serve stroke survivors and other patients with upper‑limb impairments. Skelable’s engineering team, with more than 60 years of combined experience, will join Lifeward, bringing expertise that is expected to accelerate product development.
Market data indicate that 245,000 new stroke survivors are diagnosed each year in the United States, and an estimated 4.6 million stroke survivors remain disabled. The upper‑limb market represents a significant unmet need, and Lifeward’s acquisition positions it to capture a share of this growing segment. Lifeward expects the upper‑body exoskeleton to be ready for commercial launch within 18 to 24 months, following additional development and regulatory approvals.
Lifeward’s financial profile is a key context for the transaction. Recent reports show the company has experienced significant operating losses and declining gross margins in Q4 2024, and it has been working to regain compliance with Nasdaq’s listing requirements. The equity‑based payment structure for the acquisition helps conserve cash while allowing Lifeward to expand its product portfolio amid financial constraints. The deal also dovetails with Lifeward’s broader strategy of diversification, which includes a January 2026 partnership with Oramed Pharmaceuticals that adds a biotech dimension to its MedTech focus.
The acquisition is expected to close in the coming months, subject to customary closing conditions. Lifeward’s management views the transaction as a strategic step toward a full‑body neuro‑rehabilitation solution and a means to leverage its existing customer base of physical medicine and rehabilitation physicians, neurologists, and veterans’ affairs facilities for cross‑sell opportunities. The move is intended to strengthen Lifeward’s competitive position in the broader rehabilitation device sector while addressing a critical market opportunity for upper‑limb neuro‑rehabilitation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.